Economic burden of cervical cancer in Malaysia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cervical cancers form the second highest number of female cancers in Malaysia, imposing a substantial amount of cost burden on its management. However, an estimation of cost burden of abnormal smears, cervical pre-invasive and invasive diseases needs to be done to show how much spending has been allocated to the problem. An expert panel committee came up with the clinical pathway and management algorithm of cervical pre invasive and invasive diseases from July-December 2006 Malaysia. An activity based costing for each clinical pathway was done. Results were converted to USD. The cost of managing pre-invasive cervical cancers stage is USD 420,150 (Range: USD 197,158-879,679). Management of invasive cancer (new cases) costs USD 51,533,233.44 (Range: USD 32,405,399.69 - USD 129,014,768.40). The cost of managing existing cases is USD 17,005,966.87 (Range: USD 10,693,781.90 - USD 28,901,587.12). The total cost of managing cervical cancers by health care providers in a public setting is around USD 75,888,329.45 (Range: USD 48,083,804.60 - USD 48,083,804.60). The outcome of this study has shown that preventive modalities such as screening have only contributed to 10.3% of the total management cost of cervical cancer. The major cost contribution (67%) came from treatment of invasive cancer especially at more advanced stages of cancer, followed by treatment of existing cases (22%) and lastly on pre-invasive disease (0.6%). This study revealed that proportion of preventive modality in this country was still low, and the major cost came from actual treatment cost of cervical cancer. Therefore, heightened public cervical cancer screening in the country is needed.

Original languageEnglish
Pages (from-to)272-280
Number of pages9
JournalMedical Journal of Indonesia
Volume17
Issue number4
DOIs
Publication statusPublished - 1 Oct 2008

Fingerprint

Malaysia
Uterine Cervical Neoplasms
Economics
Costs and Cost Analysis
Critical Pathways
Neoplasms
Vaginal Smears
Early Detection of Cancer
Health Personnel
Health Care Costs
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Cervical cancers
  • HPV vaccination
  • Pre invasive disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Economic burden of cervical cancer in Malaysia. / Wan Puteh, Sharifa Ezat; Ng, Paul; Syed Junid, Syed Mohamed Al-Junid.

In: Medical Journal of Indonesia, Vol. 17, No. 4, 01.10.2008, p. 272-280.

Research output: Contribution to journalArticle

@article{482f7fbe20d4404e87a71bd1ff7e6157,
title = "Economic burden of cervical cancer in Malaysia",
abstract = "Cervical cancers form the second highest number of female cancers in Malaysia, imposing a substantial amount of cost burden on its management. However, an estimation of cost burden of abnormal smears, cervical pre-invasive and invasive diseases needs to be done to show how much spending has been allocated to the problem. An expert panel committee came up with the clinical pathway and management algorithm of cervical pre invasive and invasive diseases from July-December 2006 Malaysia. An activity based costing for each clinical pathway was done. Results were converted to USD. The cost of managing pre-invasive cervical cancers stage is USD 420,150 (Range: USD 197,158-879,679). Management of invasive cancer (new cases) costs USD 51,533,233.44 (Range: USD 32,405,399.69 - USD 129,014,768.40). The cost of managing existing cases is USD 17,005,966.87 (Range: USD 10,693,781.90 - USD 28,901,587.12). The total cost of managing cervical cancers by health care providers in a public setting is around USD 75,888,329.45 (Range: USD 48,083,804.60 - USD 48,083,804.60). The outcome of this study has shown that preventive modalities such as screening have only contributed to 10.3{\%} of the total management cost of cervical cancer. The major cost contribution (67{\%}) came from treatment of invasive cancer especially at more advanced stages of cancer, followed by treatment of existing cases (22{\%}) and lastly on pre-invasive disease (0.6{\%}). This study revealed that proportion of preventive modality in this country was still low, and the major cost came from actual treatment cost of cervical cancer. Therefore, heightened public cervical cancer screening in the country is needed.",
keywords = "Cervical cancers, HPV vaccination, Pre invasive disease",
author = "{Wan Puteh}, {Sharifa Ezat} and Paul Ng and {Syed Junid}, {Syed Mohamed Al-Junid}",
year = "2008",
month = "10",
day = "1",
doi = "10.13181/mji.v17i4.330",
language = "English",
volume = "17",
pages = "272--280",
journal = "Medical Journal of Indonesia",
issn = "0853-1773",
publisher = "Faculty of Medicine Universitas Indonesia",
number = "4",

}

TY - JOUR

T1 - Economic burden of cervical cancer in Malaysia

AU - Wan Puteh, Sharifa Ezat

AU - Ng, Paul

AU - Syed Junid, Syed Mohamed Al-Junid

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Cervical cancers form the second highest number of female cancers in Malaysia, imposing a substantial amount of cost burden on its management. However, an estimation of cost burden of abnormal smears, cervical pre-invasive and invasive diseases needs to be done to show how much spending has been allocated to the problem. An expert panel committee came up with the clinical pathway and management algorithm of cervical pre invasive and invasive diseases from July-December 2006 Malaysia. An activity based costing for each clinical pathway was done. Results were converted to USD. The cost of managing pre-invasive cervical cancers stage is USD 420,150 (Range: USD 197,158-879,679). Management of invasive cancer (new cases) costs USD 51,533,233.44 (Range: USD 32,405,399.69 - USD 129,014,768.40). The cost of managing existing cases is USD 17,005,966.87 (Range: USD 10,693,781.90 - USD 28,901,587.12). The total cost of managing cervical cancers by health care providers in a public setting is around USD 75,888,329.45 (Range: USD 48,083,804.60 - USD 48,083,804.60). The outcome of this study has shown that preventive modalities such as screening have only contributed to 10.3% of the total management cost of cervical cancer. The major cost contribution (67%) came from treatment of invasive cancer especially at more advanced stages of cancer, followed by treatment of existing cases (22%) and lastly on pre-invasive disease (0.6%). This study revealed that proportion of preventive modality in this country was still low, and the major cost came from actual treatment cost of cervical cancer. Therefore, heightened public cervical cancer screening in the country is needed.

AB - Cervical cancers form the second highest number of female cancers in Malaysia, imposing a substantial amount of cost burden on its management. However, an estimation of cost burden of abnormal smears, cervical pre-invasive and invasive diseases needs to be done to show how much spending has been allocated to the problem. An expert panel committee came up with the clinical pathway and management algorithm of cervical pre invasive and invasive diseases from July-December 2006 Malaysia. An activity based costing for each clinical pathway was done. Results were converted to USD. The cost of managing pre-invasive cervical cancers stage is USD 420,150 (Range: USD 197,158-879,679). Management of invasive cancer (new cases) costs USD 51,533,233.44 (Range: USD 32,405,399.69 - USD 129,014,768.40). The cost of managing existing cases is USD 17,005,966.87 (Range: USD 10,693,781.90 - USD 28,901,587.12). The total cost of managing cervical cancers by health care providers in a public setting is around USD 75,888,329.45 (Range: USD 48,083,804.60 - USD 48,083,804.60). The outcome of this study has shown that preventive modalities such as screening have only contributed to 10.3% of the total management cost of cervical cancer. The major cost contribution (67%) came from treatment of invasive cancer especially at more advanced stages of cancer, followed by treatment of existing cases (22%) and lastly on pre-invasive disease (0.6%). This study revealed that proportion of preventive modality in this country was still low, and the major cost came from actual treatment cost of cervical cancer. Therefore, heightened public cervical cancer screening in the country is needed.

KW - Cervical cancers

KW - HPV vaccination

KW - Pre invasive disease

UR - http://www.scopus.com/inward/record.url?scp=85008940798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008940798&partnerID=8YFLogxK

U2 - 10.13181/mji.v17i4.330

DO - 10.13181/mji.v17i4.330

M3 - Article

VL - 17

SP - 272

EP - 280

JO - Medical Journal of Indonesia

JF - Medical Journal of Indonesia

SN - 0853-1773

IS - 4

ER -